公开(公告)号：US12084696B2

公开(公告)日：2024-09-10

申请号：US18501966

申请日：2023-11-03

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Henry M. Colecraft ,  Scott Kanner

IPC分类号： C12N9/64 ,  A61K38/00 ,  C12N15/85 ,  C12Q1/6883

CPC分类号： C12N9/6472 ,  C12N15/85 ,  C12Q1/6883 ,  C12Y304/22 ,  A61K38/00 ,  C12Q2600/156

摘要： The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

公开(公告)号：US11845967B2

公开(公告)日：2023-12-19

申请号：US16867923

申请日：2020-05-06

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Henry M. Colecraft ,  Scott Kanner

IPC分类号： C12N9/64 ,  C12N15/85 ,  C12Q1/6883 ,  A61K38/00

CPC分类号： C12N9/6472 ,  C12N15/85 ,  C12Q1/6883 ,  C12Y304/22 ,  A61K38/00 ,  C12Q2600/156

摘要： The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

公开(公告)号：US20240067946A1

公开(公告)日：2024-02-29

申请号：US18501967

申请日：2023-11-03

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Henry M. Colecraft ,  Scott Kanner

IPC分类号： C12N9/64 ,  C12N15/85 ,  C12Q1/6883

CPC分类号： C12N9/6472 ,  C12N15/85 ,  C12Q1/6883 ,  C12Y304/22 ,  A61K38/00

摘要： The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

公开(公告)号：US20200263159A1

公开(公告)日：2020-08-20

申请号：US16867923

申请日：2020-05-06

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Henry M. Colecraft ,  Scott Kanner

IPC分类号： C12N9/64 ,  C12N15/85 ,  C12Q1/6883

摘要： The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

公开(公告)号：US12091695B2

公开(公告)日：2024-09-17

申请号：US18501967

申请日：2023-11-03

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Henry M. Colecraft ,  Scott Kanner

IPC分类号： C12N9/64 ,  A61K38/00 ,  C12N15/85 ,  C12Q1/6883

CPC分类号： C12N9/6472 ,  C12N15/85 ,  C12Q1/6883 ,  C12Y304/22 ,  A61K38/00 ,  C12Q2600/156

摘要： The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

公开(公告)号：US20240067945A1

公开(公告)日：2024-02-29

申请号：US18501966

申请日：2023-11-03

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Henry M. Colecraft ,  Scott Kanner

IPC分类号： C12N9/64 ,  C12N15/85 ,  C12Q1/6883

CPC分类号： C12N9/6472 ,  C12N15/85 ,  C12Q1/6883 ,  C12Y304/22 ,  A61K38/00

摘要： The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.